Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

In8bio Appoints Oxana Polyakova, Ph.D. As Senior Vice President of R&D

PUBLIC · INABSep 09, 2026•about 2 hours ago

Position

Senior Vice President

Company

IN8bio

Oxana Polyakova, Ph.D.
New YorkBiotechnologyTherapeutics

Description

IN8bio, Inc. has announced the appointment of Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development. Dr

Company Information

Company

IN8bio

Location

New York, New York, United States

About

IN8bio is a clinical-stage biopharmaceutical company advancing gamma-delta T cell therapies for the treatment of cancer, leveraging its proprietary DeltEx platform to develop ex vivo–expanded, activated, and genetically modified cell therapies using allogeneic and autologous approaches. As the most clinically advanced company in this field, IN8bio combines deep expertise in gamma-delta T cell biology, genetic engineering, and specialized manufacturing to design novel therapies that precisely identify and eradicate tumor cells.

Don't miss IN8bio's next move

Get an email the moment IN8bio changes its leadership, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Suggested for you
Patrick
Likely contact at this company
••••••••@••••••••

See Patrick's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for IN8bio's next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

IN8bio changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.